BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25613299)

  • 1. Novel treatments for idiopathic pulmonary fibrosis.
    Spagnolo P
    Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
    [No Abstract]   [Full Text] [Related]  

  • 2. Two therapies now available for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185
    [No Abstract]   [Full Text] [Related]  

  • 3. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 4. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
    Ryerson CJ; Collard HR
    Thorax; 2014 Sep; 69(9):791-2. PubMed ID: 24996636
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic advances in idiopathic pulmonary fibrosis.
    George G; Vaid U; Summer R
    Clin Pharmacol Ther; 2016 Jan; 99(1):30-2. PubMed ID: 26502087
    [No Abstract]   [Full Text] [Related]  

  • 6. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 7. New guideline on treatment of idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Maher TM
    Lancet Respir Med; 2015 Sep; 3(9):e31-e32. PubMed ID: 26380887
    [No Abstract]   [Full Text] [Related]  

  • 8. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
    Kingwell K
    Nat Rev Drug Discov; 2014 Jul; 13(7):483-4. PubMed ID: 24981347
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial research in focus: why do so many clinical trials fail in IPF?
    Spagnolo P; Maher TM
    Lancet Respir Med; 2017 May; 5(5):372-374. PubMed ID: 28412184
    [No Abstract]   [Full Text] [Related]  

  • 12. Update in Interstitial Lung Disease 2014.
    Belloli EA; Martinez FJ; Flaherty KR
    Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676
    [No Abstract]   [Full Text] [Related]  

  • 13. Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2.
    Guler SA; Lindell KO; Swigris J; Ryerson CJ
    Am J Respir Crit Care Med; 2021 Feb; 203(3):P7-P8. PubMed ID: 33522880
    [No Abstract]   [Full Text] [Related]  

  • 14. A new era of drug therapy for idiopathic pulmonary fibrosis.
    Crooks MG; Hart SP
    Lancet Respir Med; 2014 Dec; 2(12):964-6. PubMed ID: 25466348
    [No Abstract]   [Full Text] [Related]  

  • 15. [The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
    Kashiwada T; Azuma A
    Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):970-6. PubMed ID: 30168687
    [No Abstract]   [Full Text] [Related]  

  • 16. New treatments in idiopathic pulmonary fibrosis.
    Strâmbu I
    Pneumologia; 2016; 65(3):127-32. PubMed ID: 29542881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifibrotic treatment].
    von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
    [No Abstract]   [Full Text] [Related]  

  • 19. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 20. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
    Brown KK
    Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.